TCPG
MRNA icon

Trivant Custom Portfolio Group’s Moderna MRNA Stock Holding History

Trivant Custom Portfolio Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20
Closed -$567 – 164
2025
Q1 		$567 Hold
20
– – ﹤0.01% 190
2024
Q4 		$832 Sell
20
-100
-83% -$4.78K ﹤0.01% 189
2024
Q3 		$8.02K Buy
+120
New +$11K ﹤0.01% 142
2023
Q4 		– Sell
-9,988
Closed -$1.03M – 214
2023
Q3 		$1.03M Sell
9,988
-9
-0.1% -$1K 0.76% 41
2023
Q2 		$1.21M Buy
9,997
+374
+4% +$49.9K 0.86% 41
2023
Q1 		$1.48M Buy
+9,623
New +$1.59M 1.06% 37

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Trivant Custom Portfolio Group's MRNA Position: Q2 2025 in Review

Trivant Custom Portfolio Group sold out of Moderna (MRNA) in Q2 2025, closing a stake of 20 shares — an estimated $567 sold.

Trivant Custom Portfolio Group first reported a position in MRNA in Q1 2023 and held it in 6 quarters. The position peaked at $1.48M in Q1 2023. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

  • Trivant Custom Portfolio Group reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
  • Trivant Custom Portfolio Group sold 20 Moderna shares in Q2 2025, an estimated $567.
  • Trivant Custom Portfolio Group first reported a position in Moderna in Q1 2023 and held it in 6 quarters.
  • Trivant Custom Portfolio Group's Moderna position peaked at $1.48M in Q1 2023.
  • 674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on Trivant Custom Portfolio Group's 13F filing for Q2 2025, filed 12 Aug 2025.